| Literature DB >> 32747501 |
Satoru Watanabe1, Masayuki Fujino1, Yohei Saito1,2, Nursarat Ahmed1, Hirotaka Sato1, Chie Sugimoto3, Tomotaka Okamura2, Kenichi Hanaki4, Emi E Nakayama5, Tatsuo Shioda5, Kouji Matsushima6, Aftab A Ansari7, Francois Villinger8, Kazuyasu Mori9,2,6.
Abstract
Deglycosylated, live-attenuated SIV vaccines elicited protective immune responses against heterologous SIVsmE543-3, which differs from the vaccine strain SIVmac239 to levels similar to those across HIV-1 clades. Two thirds of the vaccinees contained the chronic SIVsmE543-3 infection (controllers), whereas one third did not (noncontrollers). In this study, we investigated immune correlates of heterologous challenge control in rhesus macaques of Burmese origin. Because depletion of CD8+ cells in the controllers by administration of anti-CD8α Ab abrogated the control of viral replication, CD8+ cells were required for the protective immune response. However, classical SIV-specific CD8+ T cells did not account for the protective immune response in all controllers. Instead, IL-15-responding CD8α+ cells, including CD8+ T and NK cells, were significantly higher in the controllers than those in the noncontrollers, before and after vaccination with deglycosylated SIV. It is well established that IL-15 signal transduction occurs through "trans-presentation" in which IL-15 complexed with IL-15Rα on monocytes, macrophages, and dendritic cells binds to IL-15 Rβ/γ expressed on CD8+ T and NK cells. Accordingly, levels of IL-15 stimulation were strongly affected by the depletion of monocytes from PBMCs, implying key roles of innate immune cells. These results suggest that intrinsic IL-15 responsiveness may dictate the outcome of protective responses and may lead to optimized formulations of future broadly protective HIV vaccines.Entities:
Year: 2020 PMID: 32747501 PMCID: PMC7484436 DOI: 10.4049/jimmunol.1901431
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422